| Literature DB >> 34219448 |
Yury Valdes-Balbin1, Darielys Santana-Mederos1, Lauren Quintero1, Sonsire Fernández1, Laura Rodriguez1, Belinda Sanchez Ramirez2, Rocmira Perez-Nicado1, Claudia Acosta1, Yanira Méndez3, Manuel G Ricardo3, Tays Hernandez2, Gretchen Bergado2, Franciscary Pi2, Annet Valdes2, Tania Carmenate2, Ubel Ramirez1, Reinaldo Oliva1, Jean-Pierre Soubal1, Raine Garrido1, Felix Cardoso1, Mario Landys1, Humberto Gonzalez1, Mildrey Farinas1, Juliet Enriquez4, Enrique Noa4, Anamary Suarez4, Cheng Fang5, Luis A Espinosa6, Yassel Ramos6, Luis Javier González6, Yanet Climent1, Gertrudis Rojas2, Ernesto Relova-Hernández2, Yanelys Cabrera Infante2, Sum Lai Losada2, Tammy Boggiano2, Eduardo Ojito2, Kalet León2, Fabrizio Chiodo1,7,8, Françoise Paquet9, Guang-Wu Chen10, Daniel G Rivera3, Dagmar Garcia-Rivera1, Vicente Verez Bencomo1.
Abstract
Controlling the global COVID-19 pandemic depends, among other measures, on developing preventive vaccines at an unprecedented pace. Vaccines approved for use and those in development intend to elicit neutralizing antibodies to block viral sites binding to the host's cellular receptors. Virus infection is mediated by the spike glycoprotein trimer on the virion surface via its receptor binding domain (RBD). Antibody response to this domain is an important outcome of immunization and correlates well with viral neutralization. Here, we show that macromolecular constructs with recombinant RBD conjugated to tetanus toxoid (TT) induce a potent immune response in laboratory animals. Some advantages of immunization with RBD-TT conjugates include a predominant IgG immune response due to affinity maturation and long-term specific B-memory cells. These result demonstrate the potential of the conjugate COVID-19 vaccine candidates and enable their advance to clinical evaluation under the name SOBERANA02, paving the way for other antiviral conjugate vaccines.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34219448 DOI： 10.1021/acschembio.1c00272
Source DB: PubMed Journal: ACS Chem Biol ISSN： 1554-8929 Impact factor: 5.100